肌萎缩侧索硬化症脑脊液中生物标记物研究进展  

Research advances incerebrospinal fluid biomarkers for amyotrophic lateral sclerosis

作　　者：王虹杨 翁超[1] 卢祖能[1] WANG Hong-Yang;WENG Chao;LU Zu-Neng(Department of Neurology,Renmin Hospital of Wuhan University,Wuhan,Hubei 430060,China)

机构地区：[1]武汉大学人民医院神经内科,湖北武汉430060

出　　处：《国际神经病学神经外科学杂志》2021年第4期392-395,共4页Journal of International Neurology and Neurosurgery

摘　　要：肌萎缩侧索硬化症是一种慢性进展性疾病,目前病因及发病机制不明,尚无有效的生物标志物协助疾病诊断、判断疾病进展及预后。生物标记物研究通过对病理生理机制的探索可以加深对疾病的理解,有助于疾病诊断、分类、药效学检测,及识别新的药物靶点,为新疗法实施提供方向。Amyotrophic lateral sclerosis(ALS)is a chronic progressive disease with unknown etiology and pathogenesis,and there are still no effective biomarkers to assist in the diagnosis,progression judgment,and prognostic evaluation of the disease.The research on biomarkers can deepen the understanding of disease by exploring pathophysiological mechanisms and help with disease diagnosis,classification,pharmacodynamic detection,and identification of new drug targets,thereby providing a direction for the implementation of new therapies.

关 键 词：肌萎缩侧索硬化症 脑脊液 生物标记物 

分 类 号：R744.8[医药卫生—神经病学与精神病学]